1. The quadrivalent recombinant influenza vaccine (RIV4) was noninferior when compared with the quadrivalent inactivated influenza vaccine (IIV4) for immunogenicity. Evidence Rating Level: 1 (Excellent) Study Rundown: Seasonal influenza vaccines have recently been transitioned to a quadrivalent, recombinant formulation to provide broadened protection against 2 antigenically distinct influenza type B lineages in addition to the […]
↧